Scientific deep-dive

Are Peptides Legal? 2026 Rules for Compounded vs Research Peptides

FDA-approved peptide drugs are legal by prescription. A draft October 2026 HHS policy says HHS does not intend to enforce against 503A compounding of six peptides, including BPC-157 and TB-500, under ten conditions. Research-chemical peptides are still not legal for human use.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
12 min read·10 citations

“Are peptides legal?” is one of those questions that sounds simple and has a genuinely complicated answer. The short version: it depends entirely on which peptide, in what form, from what source. Some peptides — semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), liraglutide (Saxenda) — are FDA-approved drugs available by prescription with a full regulatory quality record. Others can be legally obtained through the narrow regulated pathway of compounding pharmacies under specific, documented conditions. A large third category — sold online under the label “for research use only, not for human consumption” — are gray-market research chemicals whose purchase for personal human use is not legally sanctioned, and whose identity, purity, sterility, and dose are verified by no agency. On top of all that, competitive athletes face an additional layer: the World Anti-Doping Agency (WADA) prohibits an entire category of peptide hormones and growth factors regardless of where they were obtained. The 2026 change: on October 28, 2026, HHS announced an interim policy for six peptides (BPC-157, TB-500, Epitalon, KPV, MOTS-c, and Semax). When ten conditions are met, HHS says it does not intend to bring enforcement action against the 503A pharmacies, licensed physicians, or Federal facilities that compound them[9]. That is enforcement discretion, not FDA approval, and it does not cover research-chemical sellers. HHS published the policy in the Federal Register on October 30, 2026 as a draft, non-binding policy with a two-week window for written comments; it is not a rule[10]. Our news report covers the announcement. This article explains each tier, walks through what changed for those six peptides (our full explainer on the HHS 503A peptide policy covers the policy itself), and maps the real risks of buying unregulated peptides. It is an evidence and regulatory explainer — not a dosing guide or sourcing recommendation.

  • Tier 1 — FDA-approved prescription peptide drugs (legal with a valid prescription). Semaglutide (Wegovy / Ozempic), tirzepatide (Zepbound / Mounjaro), liraglutide (Saxenda / Victoza), and dulaglutide (Trulicity) are all peptide-based drugs with full FDA new drug application (NDA) approval. They have large Phase-3 human randomized trials behind them[1][2], FDA-regulated manufacturing, and verified identity, purity, and dose. Purchasing and using them requires a valid prescription from a licensed US prescriber — full stop. Our FDA-approved peptides list sets out which peptides are FDA-approved beyond the GLP-1 drugs.
  • Tier 2 — Compounded peptides through licensed pharmacies (legal in narrow circumstances). Compounding pharmacies — operating under the FDA’s 503A or 503B framework — can prepare certain peptide formulations for patients when specific legal conditions are met. For GLP-1s, this path narrowed significantly after the semaglutide shortage resolution in February 2025 (see compounded semaglutide FDA status). For most other peptides, a 503A pharmacy is limited to bulk substances that fall into one of three groups (those with a USP monograph, those already used in an FDA-approved drug, and those on FDA’s 503A bulks list), and each prescription has to name an individual patient[7][9]. Since October 28, 2026, six peptides get interim special treatment under a draft HHS policy that binds neither HHS nor the public: for BPC-157, TB-500, Epitalon, KPV, MOTS-c, or Semax, HHS says it does not intend to bring enforcement action against 503A compounders who satisfy all ten of its conditions, including a patient-specific prescription, a single active ingredient, an allowed route, and a certificate of analysis from an FDA-registered manufacturer[9]. The policy does not make these drugs FDA-approved.
  • Tier 3 — Gray-market “research chemicals” (not approved for human use, legally ambiguous, no quality guarantee). This is the category that drives most of the “are peptides legal?” confusion. Products labeled “for research use only — not for human consumption” are not FDA-approved drugs. The disclaimer is a seller’s legal shield, not a quality guarantee, and it does not legalize personal injection or ingestion for human therapeutic use. No agency has verified the identity, purity, sterility, or dose of what is in those vials.
  • Bonus tier for athletes — WADA S2 prohibition (banned in all competitive sport, regardless of source). Even a legally compounded peptide can be prohibited for a competitive athlete. WADA’s S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics) bans a wide range of peptides in and out of competition, with no approved therapeutic use exemption (TUE) for most of them[6].

What "for research use only — not for human consumption" actually means legally

This disclaimer is the legal architecture of the gray-market peptide industry. Vendors selling BPC-157, TB-500, CJC-1295, ipamorelin, or dozens of other synthetic peptides use it to avoid being charged with distributing unapproved drugs for human use. Their position is: we sold it for research; what the customer does next is the customer’s decision.

This argument has serious limits. Under the Federal Food, Drug, and Cosmetic Act, a peptide that is not FDA-approved as a drug product but is intended for human therapeutic use is an unapproved new drug — and its distribution for that purpose is unlawful whether or not the package says “for research use only.” Marketing that implies human therapeutic use (dosing tables matching clinical doses, before-and-after customer reviews, injection-site diagrams) can undermine the research-use defense entirely. And from the buyer’s standpoint, the disclaimer provides zero quality assurance: it does not mean the product was tested for identity, purity, sterility, or dose accuracy.

The FDA has been explicit about this. Its standing advisory on unapproved GLP-1 products — which applies the same reasoning to peptides broadly — states that unapproved drug products do not undergo FDA review for safety, effectiveness, or quality, and that consumers who use them do so without the safety net of the federal drug-approval system[8].

Three things the “research use only” label is not

  • It is not a legal license to inject or ingest the product for human therapeutic use.
  • It is not a quality or purity guarantee — no identity, sterility, or dose testing is implied.
  • It is not equivalent to a prescription, FDA approval, or 503A/503B compounding authority.

FDA compounding categories: 503A vs 503B

For peptides that exist outside the gray-market — those that might legitimately be prepared by a compounding pharmacy — the FDA’s Drug Quality and Security Act (DQSA) creates two distinct regulated pathways[7][8]:

  • 503A — traditional compounding pharmacies (state-licensed). A 503A pharmacy can compound a drug for an individually-identified patient pursuant to a valid prescription from a licensed prescriber. The prescriber must document a clinical reason that the FDA-approved product cannot meet for that specific patient — a documented allergy to an inactive ingredient, a dose not commercially available, or a documented clinical need. “It’s cheaper” does not qualify. 503A pharmacies can only compound substances that are not on FDA’s prohibited-for-compounding list and that have a legitimate clinical basis.
  • 503B — outsourcing facilities (FDA-registered, bulk compounding). 503B outsourcing facilities may compound larger batches without patient-specific prescriptions, but they may only compound from bulk drug substances on FDA’s 503B Bulks List (or substances on the active shortage list). If a substance is not on that list, 503B facilities cannot lawfully compound it. The list is maintained by FDA after evaluation of clinical need and safety[8].

Both pathways require a real prescriber, a real state-licensed or FDA-registered pharmacy, and substances that meet the relevant FDA standards. Neither pathway applies to self-purchased gray-market research peptides.

BPC-157 and five other peptides: from Category 2 to HHS enforcement discretion

According to the HHS policy’s Appendix B, BPC-157, TB-500, Epitalon, KPV, MOTS-c, and Semax were each in FDA’s Category 2 of nominated bulk drug substances starting in September 2023, and they came off that list on April 22, 2026. CDER, FDA’s drug center, advised against putting each one on the 503A bulks list; the Pharmacy Compounding Advisory Committee (PCAC) voted the other way. Appendix B adds that their section 503A status was not affected either by going into Category 2 or by coming out of it[9]. Until late October 2026, that left no recognized compounding pathway for any of the six.

On October 28, 2026, HHS announced an interim enforcement-discretion policy that applies while FDA develops the 503A bulks list through rulemaking. The Federal Register notice of October 30 describes it as a draft binding on neither HHS nor the public[10]. If a licensed physician, a Federal facility, or a State-licensed pharmacy compounds one of the six peptides and satisfies all ten conditions, HHS says it does not intend to bring enforcement action against it. Its stated aims are to draw patients off the research-use-only peptides that overseas manufacturers produce and to widen patient choice, and it keeps the option of reopening the policy should safety signals or quality defects emerge[9]. The document repeats that compounded drugs lack FDA approval and go unreviewed by FDA for safety, effectiveness, or quality. None of the six has a published human trial establishing benefit for the uses it is marketed for[3][4].

Routes Appendix B permits for each of the six peptides in the interim HHS policy
PeptideForm named in Appendix BRoutes covered
BPC-157BPC-157 acetateSubcutaneous, intramuscular, oral, topical
TB-500TB-500 acetate (Ac-LKKTETQ)Subcutaneous or intramuscular
EpitalonEpitalon acetateSubcutaneous or intramuscular, dispensed in intermittent courses
KPVKPV acetateTopical and oral
MOTS-cMOTS-c acetateSubcutaneous or intramuscular
SemaxSemax free baseIntranasal only

The ten conditions, in short: the peptide is on Appendix A; it matches the identity and route in Appendix B; the bulk substance is sourced from a facility registered under section 510 and carries a valid certificate of analysis that tests identity, purity, and potency and screens for endotoxin, heavy metals, microbial contamination, and impurities; the original manufacturer is FDA-registered, works under current good manufacturing practice, and appears by name on the certificate; the compounder files reports with FDA MedWatch and the States on what it compounds, on serious adverse events, and on quality defects; the label carries the sentence “This is a compounded drug product. Not for resale.”; the product contains a single active ingredient; oral forms have documentation of adequate oral bioavailability in humans; the only co-packaged device is an FDA 510(k)-cleared syringe; and every other FD&C Act requirement applies, including a patient-specific prescription and sanitary conditions[9].

What the policy does not cover matters just as much. It names 503A pharmacies, Federal facilities, and physicians, not 503B outsourcing facilities. Premixed blends and stacks (for example BPC-157 combined with TB-500 in one vial) fail the single-ingredient condition. And the same molecules sold online as “research use only” are still Tier 3 products: nothing in the policy makes them lawful for human use[9]. For the practical steps with the most-requested peptide, see how to get BPC-157 online through a prescriber and a 503A pharmacy.

Peptides not named in Appendix A, such as CJC-1295 or AOD-9604, get no cover from this policy. The same goes for adipotide, a fat-loss peptide with dramatic monkey data and no completed human obesity trial. The GLP-1 compounding story — involving a different set of peptides that did have FDA-approved status but were removed from the shortage list in 2025 — illustrates how quickly the regulatory landscape can shift for any peptide category. See our compounded semaglutide FDA status guide and the parallel compounding pharmacy guide for the GLP-1 version of this story.

Peptide regulatory status — where the major categories land
Peptide categoryLegal pathway in the USQuality verification
FDA-approved GLP-1 peptide drugs
Semaglutide (Wegovy/Ozempic), tirzepatide (Zepbound/Mounjaro), liraglutide (Saxenda)
Legal by prescription from a licensed US prescriber. Full NDA approval[1][2]Yes — FDA-regulated manufacturing: identity, purity, sterility, dose verified
503A compounded peptides
Patient-specific, state-licensed pharmacy
Legal under narrow conditions with a patient-specific prescription. GLP-1s: only post-shortage if criteria met[7][8]. BPC-157, TB-500, Epitalon, KPV, MOTS-c, Semax: draft HHS enforcement discretion since Oct 28, 2026, single ingredient and allowed routes only; not FDA approval[9]Partial: state-licensed pharmacy; for the six, a certificate of analysis from an FDA-registered manufacturer is required. NOT equivalent to an FDA-approved product
503B bulk-compounded peptides
Outsourcing facilities, batch compounding
Legal ONLY for substances on FDA 503B Bulks List (or on the shortage list). The draft 2026 HHS peptide policy covers 503A compounders, not 503B facilities[8][9]FDA-registered facility, but substance itself may lack clinical data
Gray-market “research chemical” peptides
BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604, etc.
Not approved for human use. “Research use only” disclaimer does not legalize personal therapeutic use, and the draft 2026 HHS policy does not cover these sellers. Buying for self-injection is legally and medically unsupportedNone — no FDA review of identity, purity, sterility, or dose
WADA-prohibited peptides (competitive athletes)
S2: GHRPs, CJC-1295, ipamorelin, TB-500, IGF-1, etc. S0: BPC-157.
Banned in and out of competition under WADA S2 (BPC-157: S0). No approved TUE for most. Applies regardless of how the peptide was obtained[6]Not applicable — prohibited category regardless of source

WADA S2: what competitive athletes need to know

For athletes subject to anti-doping rules, there is a separate and stricter layer of restriction. WADA’s 2026 Prohibited List, Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibits a broad category of peptides both in-competition and out-of-competition[6]. The S2 category includes:

  • Growth hormone-releasing peptides (GHRPs): GHRP-2, GHRP-6, ipamorelin, and related compounds are explicitly named.
  • Growth hormone-releasing factors and analogs: CJC-1295, sermorelin (when used as a growth-axis secretagogue rather than a medically supervised approved drug).
  • Thymosin β4 and its analogs and fragments — a category that explicitly encompasses TB-500.
  • “Other similar substances” — a catch-all provision meaning WADA does not need to name every synthetic peptide individually; substances with similar pharmacological activity fall under S2 by analogy[5][6].

BPC-157 sits in a different section. WADA names it under S0, non-approved substances, rather than S2. S0 is banned at all times as well, so an athlete who tests positive for BPC-157 faces the same sanctions as for any other prohibited substance[6].

Notably, FDA-approved GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) are NOT on the WADA 2026 Prohibited List. An athlete with a valid prescription for Wegovy or Zepbound does not face a doping violation. Athletes should nonetheless re-verify this before each competition cycle, as the WADA list is updated annually[6].

Anti-doping laboratories have developed validated LC-MS/MS detection methods for research peptides including TB-500 in equine and human biological samples[5], and similar methods exist for BPC-157. The analytical capability to catch these compounds exists, and any athlete who self-administers them from a gray-market vial — regardless of intent — bears full strict-liability responsibility for a positive test.

The real risks of buying unregulated peptides

Beyond the legal questions, there is a concrete set of safety risks that apply whenever someone self-injects a gray-market peptide. The review literature is consistent: even a peptide with interesting preclinical data faces enormous translation uncertainty, and the quality risk of the unregulated supply chain is real[3][4]:

  • Unknown identity and purity. An unregulated vendor selling a vial labeled “BPC-157” has no obligation to test what is actually in it. Studies of gray-market peptide products have documented misidentification, degradation products, and contaminants. You may not be injecting what the label claims.
  • No sterility guarantee. Pharmaceutical-grade injectable drugs are manufactured under strict sterility requirements. Gray-market lyophilized powders are not. Self-reconstituting and self-injecting a non-sterile product risks abscess, cellulitis, or systemic infection.
  • Unknown dose. Even if the active ingredient is present, the actual concentration may differ substantially from the label. Peptide molecules are biologically active at microgram or milligram doses; dose errors in either direction carry risk.
  • No medical oversight. Adverse reactions — injection-site reactions, immune responses, unexpected endocrine effects — occur without a prescriber who knows what was injected or can recognize and treat the reaction.
  • Zero offsetting proven benefit. The risks above are not balanced by a demonstrated therapeutic effect. Most research peptides sold in this space lack the human randomized controlled trial evidence that would establish both efficacy and a safety signal at clinical doses[3][4]. For a health decision, “no proven harm” is not the same as “proven safe.”

Buyer caution: the gray-market peptide industry is large, active, and largely unregulated

Dozens of websites ship peptide vials to US consumers daily, relying on “research use only” labeling as their legal shield. The FDA’s enforcement resources mean that many of these operations continue without interruption for extended periods. The absence of enforcement action against a specific vendor is not evidence that its products are safe, legal, or what the label claims. The standard for a safe injectable drug — verified identity, sterility testing, dose accuracy, clinical evidence of efficacy — is not met by any gray-market peptide product.

Can a doctor prescribe peptides?

Yes — for FDA-approved peptide drugs, a licensed prescriber absolutely can and does write prescriptions. GLP-1 receptor agonists, some growth hormone analogs, and other approved peptide therapies all require a prescription. A prescriber can also, under narrow 503A conditions, order a compounded peptide formulation from a licensed pharmacy when the approved product does not meet the patient’s clinical needs. For the six peptides in the draft 2026 HHS policy, a prescriber can now write a patient-specific prescription that a 503A pharmacy fills under the policy’s conditions[9]. That prescription still does not make BPC-157, TB-500, or the others FDA-approved drugs, and no dose has been set by FDA or HHS.

If a clinic offers compounded BPC-157 or another of the six, ask: Is the pharmacy a state-licensed 503A pharmacy? Is the product a single peptide, not a blend? Is the route one Appendix B allows (Semax only as a nasal spray, KPV only topical or oral)? Can the pharmacy show the certificate of analysis naming the FDA-registered manufacturer? Does the label carry the wording the policy’s conditions specify[9], “This is a compounded drug product. Not for resale.”? A “no” to any of these puts the product outside the policy. Peptides not on Appendix A still have no recognized compounding basis. See our peptide directory for evidence-graded profiles of individual peptides, and our BPC-157 provider page for current compounding options. Check that a clinic is still trading before you pay, too: PeptidesRx, a Fort Worth platform that pitched itself as the licensed alternative to research-chemical sellers, has shown only a “temporarily closed” notice since at least August 2026.

Bottom line

Peptides are not uniformly legal or illegal — they fall into three distinct regulatory categories with very different risk profiles. FDA-approved peptide drugs like semaglutide and tirzepatide are legal, effective by the evidence of large Phase-3 trials[1][2], and quality-verified by FDA manufacturing standards. Compounded peptides can be legal through the narrow 503A/503B framework when specific conditions are met. Since October 28, 2026, a draft HHS policy has also said HHS does not intend to bring enforcement action against 503A compounders that make single-ingredient BPC-157, TB-500, Epitalon, KPV, MOTS-c, or Semax and meet all ten of its conditions[9]. That is draft, interim enforcement discretion, not approval or a finding that they work. Gray-market “research chemicals”, including vials of those same six peptides and most of the peptides marketed in sports and anti-aging communities, are not approved for human use and not verified for quality[3][4]. Competitive athletes face the additional WADA S2 prohibition on peptide hormones and growth factors, regardless of source or legality[6]. The “research use only” label is a seller’s legal shield, not a safety standard — and the absence of a human randomized trial showing benefit means any risk of injecting these compounds is unmitigated by proven effect.

Frequently Asked Questions

Not uniformly. FDA-approved peptide drugs like semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro) are entirely legal with a valid prescription — and have large Phase-3 human trials behind them. Peptides can also be obtained through licensed compounding pharmacies under the 503A/503B framework when specific conditions are met; since October 28, 2026, a draft, non-binding HHS enforcement-discretion policy also covers single-ingredient BPC-157, TB-500, Epitalon, KPV, MOTS-c, and Semax from 503A compounders, which is not FDA approval. What is NOT approved for human use is the gray-market 'research chemical' category — synthetic peptides sold online under 'for research use only' disclaimers. That label does not legalize personal injection or ingestion for therapeutic purposes, and no agency has verified the quality of those products.
Yes, for FDA-approved peptide drugs. A licensed US prescriber can prescribe semaglutide, tirzepatide, liraglutide, and other approved peptide medications. A prescriber can also order a compounded peptide formulation from a licensed 503A pharmacy for an individual patient. Since October 28, 2026, that can include BPC-157, TB-500, Epitalon, KPV, MOTS-c, or Semax, because a draft, non-binding HHS policy says HHS does not intend to bring enforcement action when the product is a single peptide, uses an allowed route, comes from an FDA-registered manufacturer with a certificate of analysis, and meets the other policy conditions. None of the six is FDA-approved, and peptides outside that list still have no recognized compounding basis.
For competitive athletes: yes. BPC-157 appears by name on the WADA Prohibited List under S0 (non-approved substances), prohibited both in-competition and out-of-competition, with no approved therapeutic use exemption. In US compounding, the answer changed in 2026. BPC-157 was in FDA's Category 2 from September 2023 until April 22, 2026, and FDA's drug center recommended against adding it to the 503A bulks list. On October 28, 2026, HHS announced a draft, non-binding policy saying it does not intend to bring enforcement action against 503A pharmacies, physicians, or Federal facilities compounding single-ingredient BPC-157 acetate (subcutaneous, intramuscular, oral, or topical) under ten conditions. It is still not FDA-approved, 503B outsourcing facilities are not covered, and 'research use only' vials remain unapproved for human use.
No. What HHS issued on October 28, 2026 is enforcement discretion rather than approval, and the Federal Register notice describes it as a non-binding draft; its public comment period closed on November 13, 2026. For six peptides (BPC-157, TB-500, Epitalon, KPV, MOTS-c, and Semax), HHS said it does not intend to bring enforcement action against 503A compounding while FDA settles the 503A bulks list through rulemaking, and it could reconsider that stance if safety signals or quality defects turn up. The same document states plainly that compounded drugs lack FDA approval and that FDA performs no review of their safety, effectiveness, or quality.
503A pharmacies are traditional state-licensed compounders that can prepare patient-specific formulations when a prescriber documents a clinical need the FDA-approved product cannot meet. 503B outsourcing facilities are FDA-registered and can compound larger batches, but ONLY from substances on FDA's approved 503B Bulks List. Most research peptides are not on the 503B Bulks List, so 503B facilities cannot compound them. The draft October 2026 HHS interim policy for BPC-157, TB-500, Epitalon, KPV, MOTS-c, and Semax applies only to 503A pharmacies, Federal facilities, and licensed physicians, with a patient-specific prescription and a single active ingredient. Peptides outside that list have no 503A route either.
No. As of the 2026 WADA Prohibited List, semaglutide, tirzepatide, liraglutide, and other FDA-approved GLP-1 receptor agonists are NOT prohibited in competitive sport — they do not appear in any prohibited category in-competition or out-of-competition. Athletes with valid prescriptions for these drugs do not face a doping violation. The WADA list is updated annually, so athletes should re-verify status before each competition cycle.
Several concrete risks: (1) unknown identity — the vial may not contain what the label claims; (2) no sterility guarantee — self-injecting a non-sterile product risks abscess or systemic infection; (3) unknown dose — actual concentration can differ substantially from the label; (4) no medical oversight for adverse reactions; (5) no offsetting proven benefit, because most gray-market peptides lack human randomized controlled trials showing efficacy at the doses sold. The 'research use only' label provides zero quality assurance — it is the seller's legal shield, not a safety standard.
It depends on the peptide and the source. Using an FDA-approved peptide drug like semaglutide or tirzepatide with a valid prescription is entirely legal. Buying gray-market 'research chemical' peptides is legally murkier: the 'for research use only, not for human consumption' label is the seller's liability shield, and distributing an unapproved peptide for human therapeutic use is unlawful under the Federal Food, Drug, and Cosmetic Act. While enforcement against individual buyers is uncommon, competitive athletes face strict-liability doping sanctions under WADA regardless of intent, and you have no legal or quality protection when you self-inject an unapproved product.
No. Anabolic steroids are synthetic derivatives of testosterone and are federally scheduled controlled substances in the US. Peptides are short chains of amino acids — a completely different chemical class — and some are FDA-approved drugs (like the GLP-1s), some are compounded, and many are unapproved 'research chemicals.' Peptides are generally not controlled substances the way anabolic steroids are, but that does not make the unapproved ones safe or legal to self-inject, and many peptides are still banned in competitive sport under WADA's separate S2 category.

References

  1. 1.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. PMID: 33567185.
  2. 2.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. PMID: 35658024.
  3. 3.Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. PMID: 41966639.
  4. 4.Mateescu DM, Gavrilescu DM, Constantinescu FE, Oancea C, Ilie AC, Folescu R, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026. PMID: 42198317.
  5. 5.Ho EN, Kwok WH, Lau MY, Wong AS, Wan TS, Lam KK, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012. PMID: 23084823.
  6. 6.World Anti-Doping Agency. The 2026 Prohibited List. International Standard. Section S0: Non-Approved Substances; Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. WADA. 2026. https://www.wada-ama.org/en/prohibited-list
  7. 7.U.S. Food and Drug Administration. Section 503A of the Federal Food, Drug, and Cosmetic Act: Compounding by a Licensed Pharmacist or Licensed Physician. FDA. 2024. https://www.fda.gov/drugs/human-drug-compounding/section-503a-federal-food-drug-and-cosmetic-act
  8. 8.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers — 503A and 503B Compounding Framework. FDA. 2024. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  9. 9.U.S. Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Appendix A and Appendix B). HHS. 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
  10. 10.U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Notice; Docket No. HHS-OASH-2026-0496; FR Doc. 2026-22192. Federal Register. 2026. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances

Is Compounded Semaglutide & Tirzepatide Legal in Your State? (2026 Tracker)

Whether compounded semaglutide and tirzepatide are legal is mostly a federal question, not a state one. Mass compounding ended after the 2025 shortage resolutions; personalized compounding remains. A sourced timeline, states with their own guidance, and telehealth shipping rules.

9 min read

How to Get a BPC-157 Prescription in 2026: 503A Pharmacy Steps and Red Flags

How to get BPC-157 online in 2026 under the draft HHS 503A policy: who can prescribe and compound it, the questions to ask a pharmacy (COA, single ingredient, label, syringe), research-chemical red flags, and what the evidence shows.

9 min read

KLOW Peptide Blend (KPV, GHK-Cu, BPC-157, TB-500): Evidence and Legal Status

What is in the KLOW peptide blend (GHK-Cu, BPC-157, TB-500, KPV), what the evidence shows for each, why there is no established dose, and why the draft 2026 HHS compounding policy does not cover blends or GHK-Cu.

9 min read

Compounded Semaglutide & Tirzepatide Are Going Away: Your 2026 Options

If your compounded semaglutide or tirzepatide is ending, you have four real paths: brand at the new lower direct-pay prices, the oral pill, tapering off, or the gray market, which we advise against. What changed in 2025 and what is still pending.

8 min read

BPC-157 vs TB-500: Recovery Peptides Compared

BPC-157 and TB-500 are both marketed for recovery, but neither has a completed human RCT. TB-500 is a fragment of thymosin beta-4, not the pharmaceutical studied in trials. Both are WADA-prohibited.

8 min read

HHS Peptide Compounding Policy (2026): What It Allows for BPC-157 and 5 Others

In a draft, non-binding policy announced October 28, 2026, HHS says it does not intend to bring enforcement action against 503A pharmacies that compound BPC-157, TB-500, MOTS-c, KPV, semax or epitalon if ten conditions are met. Only single-ingredient products qualify.

11 min read

Where to get GLP-1 safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.3

Found

Medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help

Read full review →

Pricing Compare

Get started →
8.1

Oak

Compounded semaglutide and tirzepatide at a low starting price, with a full price list before you sign up

Read full review →

Pricing Compare

Get started →
7.8

SnagRx

Compounded semaglutide and tirzepatide at a flat lifetime price

Read full review →

Pricing Compare

Get started →